shutterstock-156745016-1

Jiri Kaderabek / Shutterstock.com

29 September 2014Big PharmaArlene Chow and Peter Noh

US bio/pharma patents under attack

ore and more pharmaceutical companies are turning to the new US Patent and Trademark Office (USPTO) proceedings available under the America Invents Act (AIA) as a way to attack the validity of bio/pharma patents.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Life sciences leaders recognised at LSPN Awards USA 2025

LSPN: Counsel grapple with AI’s impact on training and critical thinking

LSPN: Trump's policy storm causing chaos and confusion

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial

Foley adds five-partner team from Perkins Coie and K&L Gates

UPC orders 17-country ban on EOFlow's pumps in Insulet feud